The daily business briefing: May 18, 2022

FDA authorizes 1st COVID booster for kids ages 5 to 11, Target shares drop as high costs hurt profit, and more

Child booster shot
(Image credit: Leon Kuegeler/Photothek/Getty Images)

1. FDA authorizes Pfizer booster for kids ages 5 to 11

The Food and Drug Administration on Tuesday authorized giving the Pfizer-BioNTech COVID-19 vaccine booster to children ages 5 to 11. Children in that age group will be eligible for the third dose of the vaccine five months after they received the second shot. The companies asked the FDA to approve the booster, the first available to children that young, based on a small study they said indicated it was safe and effective in boosting antibody levels to counter waning immunity. Previously, only people 12 or older were able to get booster shots. The companies said the booster increased protection against the coronavirus, including the highly infectious Omicron variant, which has increased the number of children hospitalized with COVID-19.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Explore More
Harold Maass, The Week US

Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.